WEED Business Summary

WEED, INC. (BUDZ) is a global cannabis and hemp bioresearch holding company that generates revenue through a multi-faceted model centered on licensing intellectual property (IP), the sale of cannabis-derived pharmaceutical and non-pharmaceutical compounds, and the leasing of commercial-grade cultivation facilities. The company’s primary business segments include genomic research and seed bank preservation (focused on rare landrace strains such as Panama Red and Acapulco Gold), international medical cannabis operations via subsidiaries in Australia and Israel, and a recently established AI/Blockchain division focused on tokenization through WEEDCoin and BUDZCoin. Direct competitors include Jaguar Health, Processa Pharmaceuticals, and Sonoma Pharmaceuticals. Relative to these peers, WEED, INC. occupies a niche micro-cap position, prioritizing genetic authentication and clinical research over the high-volume commercial cultivation typical of large-scale multi-state operators. The company is led by Co-Founder Glenn E. Martin, who serves in a consolidated leadership capacity as Chairman, President, CEO, CFO, and Chief Accounting Officer. Martin’s professional background includes 17 years as a national concert promoter, a pedigree that informs the company’s aggressive IP and branding strategy. Nicole M. Breen serves as Co-Founder, Secretary, Treasurer, and Director, maintaining a significant ownership stake alongside her spouse. Other key executives include Patrick Brodnik, Managing Director of WEED Australia Ltd., and Elliot Kwestel, who serves as Managing Director and Corporate Secretary of WEED Israel (Cannabis) Ltd. The company is characterized by high insider ownership and a lack of institutional backing, reflecting its status as a research-driven, early-stage venture.